Jin Rong Jie·2025-07-29 08:59Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Composite Index and the Hang Seng Index on July 29, with the former rising by 0.33% to close at 3609.71 points and the latter falling by 0.15% to close at 25524.45 points [1] - Fudan Zhangjiang's A/H share premium reached 171.57%, ranking fourth among A/H shares, with A shares closing at 10.75 yuan (up 2.97%) and H shares at 4.33 HKD (up 2.61%) [1] - Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] Group 2 - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [1] - Over the years, the company has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology drugs, with new products expected to be launched in the market [1] - The company has undertaken several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and the "Major New Drug Creation" science and technology major special project [1]